SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Cidofovir

Cat. No.: HY-17438

CAS No.: 113852-37-2

Molecular Formula: $C_8H_{14}N_3O_6P$

Molecular Weight: 279.19

Target: CMV; Endogenous Metabolite; DNA/RNA Synthesis; Orthopoxvirus; Apoptosis

Pathway: Anti-infection; Metabolic Enzyme/Protease; Cell Cycle/DNA Damage; Apoptosis

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

H_2O : 3.33 mg/mL (11.93 mM; Need ultrasonic)

DMSO : < 1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble or slightly soluble)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	3.5818 mL	17.9090 mL	35.8179 mL
	5 mM	0.7164 mL	3.5818 mL	7.1636 mL
	10 mM	0.3582 mL	1.7909 mL	3.5818 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
   Solubility: 4.55 mg/mL (16.30 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

BIOLOGICAL ACTIVITY

Description

Cidofovir (GS 0504) is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer[1][3]. Cidofovir also has anti-orthopoxvirus and anti-variola activities[4].

In Vitro

Cidofovir (5-100 μM, 72 hours) has antiviral activity against feline herpesvirus type-1 (FHV-1) with an IC_{50} of 11 μM, and can reduce Crandell-Reese feline kidney cell counts in a dose-dependent manner[1].

?Cidofovir (10-1000 μM, 24-120 hours) can reduce cancer cell viability and induces apoptosis[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line:	Crandell-Reese feline kidney(CRFK) cells
Concentration:	10-100 μM
Incubation Time:	72 hours
Result:	Reduced CRFK cells by 9.1%.

Cell Viability Assay[3]

Cell Line:	Caco-2, FTC-133, HeLa, Hep-G2, MDA-MB-231, NCI-H1975 and PC-3 cells
Concentration:	10-1000 μM
Incubation Time:	24, 48, 72, 96, 120 hours
Result:	Resulted in a gradual decrease in tumor cell viability with time and concentration increasing and inhibited the number of FTC-133 cell clones by about 55% at 100 μM comparing to the untreated group.

Apoptosis Analysis[3]

Cell Line:	FTC-133 cells
Concentration:	100 μM
Incubation Time:	96 hours
Result:	Showed a significant increase in the expression of pro-apoptotic proteins, such as cytochrome c, phospho-p53 (S15) and caspase-3 by 130%, 49%, and 46%, respectively while the anti-apoptotic protein Bcl-x decreased significantly by 57% comparing to the untreated cells.

In Vivo

Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days) is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female weanling BALB/c mice infected with cowpox virus (CPV)[2]
Dosage:	100 mg/kg
Administration:	Subcutaneous injection; 3-6 days interval; 21 days
Result:	Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection. Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day.

CUSTOMER VALIDATION

- Emerg Microbes Infect. 2023 May 2;2208682.
- Viruses. 2021, 13(10), 2102.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. David J Maggs, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403.

[2]. M Bray, et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis. 2000 Jan;181(1):10-9.

[3]. Simona Catalani, et al. Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir. Toxicol In Vitro. 2017 Jun;41:49-55.

[4]. Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA